• News
  • SAN DIEGO
  • BioTech

Zohydro maker sues to block Massachusetts ban

The maker of Zohydro, a controversial new prescription painkiller, has filed a lawsuit in federal court seeking to block Massachusetts' ban on local doctors prescribing and dispensing the drug.

Zogenix (Nasdaq: ZGNX) filed suit in U.S. District Court in Massachusetts on Monday requesting that the court temporarily stop Massachusetts Governor Deval Patrick's executive order. A hearing is scheduled for Tuesday afternoon, according to court records.

The San Diego-based company argues in its lawsuit that Governor Patrick's order is at odds with the U.S. Food and Drug Administration, which approved use of Zohydro for severe pain in October.

Law enforcement and public health officials fear the powerful painkiller could worsen the nation's deadly scourge of heroin and prescription drug abuse.

In March, Governor Patrick declared a public health emergency in response to the state's growing epidemic of heroin and opioid addiction. As part of that announcement, the governor gave the state public health commissioner certain emergency powers, including banning Zohydro “until determined that adequate measures are in place to safeguard against the potential for diversion, overdose, and misuse.”

The ban is an “impermissible” effort by Massachusetts to set its own drug policy, Zogenix says in its suit. “It impedes the FDA's Congressional mandate to approve a range of safe treatments to promote the public health.”

The company said the lawsuit comes after a written request to meet with Governor Patrick went unanswered. The governor's office referred questions to the state Department of Public Health, which said late Monday that it is reviewing the complaint.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Zogenix Inc.

Company Website

12400 High Bluff Dr. Ste., 650
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ZGNX
13.53
  -0.06  
- 0.44%
335,635,000
21.65
8.64

Zogenix Inc. Executive(s):

Roger Hawley

  • Chief Executive Officer

Stephen Farr

  • President

Ann Rhoads

  • Chief Financial Officer